210 related articles for article (PubMed ID: 30427266)
1. Warts and all: Fingolimod and unusual HPV-associated lesions.
Triplett J; Kermode AG; Corbett A; Reddel SW
Mult Scler; 2019 Oct; 25(11):1547-1550. PubMed ID: 30427266
[TBL] [Abstract][Full Text] [Related]
2. HPV-related papillary squamous cell carcinoma of the tonsil during treatment with fingolimod.
Benedetti MD; Marangi A; Bozzetti S; Gobbin F; Turatti M; Pea M; Gajofatto A; Mocella S
Mult Scler Relat Disord; 2018 Jul; 23():24-26. PubMed ID: 29734135
[TBL] [Abstract][Full Text] [Related]
3. Clinical commentary on "Warts and all: Fingolimod and unusual HPV associated lesions".
Macaron G; Ontaneda D
Mult Scler; 2019 Oct; 25(11):1550-1552. PubMed ID: 30427261
[No Abstract] [Full Text] [Related]
4. Approach to Fingolimod-Induced Lymphopenia in Multiple Sclerosis Patients: Do We Have a Roadmap?
Avasarala J; Jain S; Urrea-Mendoza E
J Clin Pharmacol; 2017 Nov; 57(11):1415-1418. PubMed ID: 28543950
[No Abstract] [Full Text] [Related]
5. Cryptococcal meningitis after fingolimod discontinuation in a patient with multiple sclerosis.
Ward MD; Jones DE; Goldman MD
Mult Scler Relat Disord; 2016 Sep; 9():47-9. PubMed ID: 27645342
[TBL] [Abstract][Full Text] [Related]
6. Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod.
Fragoso YD; Spelman T; Boz C; Alroughani R; Lugaresi A; Vucic S; Butzkueven H; Terzi M; Havrdova E; Horakova D; Granella F; Olascoaga J; Sánchez-Menoyo JL; Pucci E; Barnett M; Brooks JBB; Haartsen J;
Mult Scler Relat Disord; 2018 Jan; 19():105-108. PubMed ID: 29182993
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
[TBL] [Abstract][Full Text] [Related]
8. Aggressive cutaneous leishmaniasis in a patient with multiple sclerosis treated with fingolimod.
Hernández Clares R; Sánchez Pedreño P; García Vazquez E; Carreón Guarnizo E; Meca Lallana JE
Neurologia (Engl Ed); 2018 Jun; 33(5):348-349. PubMed ID: 28535923
[No Abstract] [Full Text] [Related]
9. Cryptococcal meningitis in a multiple sclerosis patient treated with Fingolimod: a case report and review of imaging findings.
Chong I; Wang KY; Lincoln CM
Clin Imaging; 2019; 54():53-56. PubMed ID: 30544079
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C virus (HCV) reactivation during fingolimod treatment for relapsing and remitting multiple sclerosis.
Tagawa A; Ogawa T; Tetsuka S; Otsuka M; Hashimoto R; Kato H; Ando K; Tanabe H
Mult Scler Relat Disord; 2016 Sep; 9():155-7. PubMed ID: 27645365
[TBL] [Abstract][Full Text] [Related]
11. Merkel cell carcinoma in a patient with relapsing-remitting multiple sclerosis treated with fingolimod.
Calvi A; De Riz M; Lecchi E; Pietroboni A; Ghezzi L; Scarioni M; Carandini T; Pellegrinelli A; Maurichi A; Galimberti D; Scarpini E
J Neurol Sci; 2017 Oct; 381():296-297. PubMed ID: 28991701
[No Abstract] [Full Text] [Related]
12. Cryptococcal meningoencephalitis in an IgG
Wienemann T; Müller AK; MacKenzie C; Bielor C; Weyers V; Aktas O; Hartung HP; Kremer D
BMC Neurol; 2020 Apr; 20(1):158. PubMed ID: 32340606
[TBL] [Abstract][Full Text] [Related]
13. Skin warts during fingolimod treatment in patients with multiple sclerosis.
Jaafar N; Zeineddine M; Massouh J; Yamout BI
Mult Scler Relat Disord; 2019 Nov; 36():101437. PubMed ID: 31606603
[TBL] [Abstract][Full Text] [Related]
14. Treatment-refractory warts associated with fingolimod.
Sahi N; Al-Araji SA; Ciccarelli O; Chard DT; Trip SA
Pract Neurol; 2022 Dec; 22(6):503-504. PubMed ID: 35981859
[No Abstract] [Full Text] [Related]
15. [Infections and fingolimod].
Cervera C
Rev Neurol; 2012 Aug; 55(4):227-37. PubMed ID: 22829086
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Outcome of WHIM Syndrome in 18 Patients: High Risk of Lung Disease and HPV-Related Malignancies.
Dotta L; Notarangelo LD; Moratto D; Kumar R; Porta F; Soresina A; Lougaris V; Plebani A; Smith CIE; Norlin AC; Gòmez Raccio AC; Bubanska E; Bertolini P; Amendola G; Visentini M; Fiorilli M; Venuti A; Badolato R
J Allergy Clin Immunol Pract; 2019; 7(5):1568-1577. PubMed ID: 30716504
[TBL] [Abstract][Full Text] [Related]
17. Varicella-zoster virus vasculopathy in a multiple sclerosis patient on fingolimod.
Muccilli A; Nehme A; Labrie M; Girard M; Odier C; Poppe AY
J Neurol Sci; 2019 Aug; 403():119-121. PubMed ID: 31276860
[No Abstract] [Full Text] [Related]
18. Update on the cardiovascular profile of fingolimod in the therapy of relapsing-remitting multiple sclerosis (MS).
Meissner A; Limmroth V
Mult Scler Relat Disord; 2016 Jul; 8():19-26. PubMed ID: 27456870
[TBL] [Abstract][Full Text] [Related]
19. Multiple sclerosis rebound after fingolimod discontinuation for lymphopenia.
La Mantia L; Prone V; Marazzi MR; Erminio C; Protti A
Neurol Sci; 2014 Sep; 35(9):1485-6. PubMed ID: 24756193
[No Abstract] [Full Text] [Related]
20. Switching to ozanimod as a strategy to adjust fingolimod-related lymphopenia.
Caliendo D; Grassia MC; Carotenuto A; Petracca M; Lanzillo R; Brescia Morra V; Moccia M
Mult Scler Relat Disord; 2024 Jan; 81():105135. PubMed ID: 38006850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
